Side-by-side · Research reference
SurvodutidevsTriptorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED25/54 cited
BFDA-ApprovedHUMAN-REVIEWED16/64 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Survodutide
Triptorelin
Primary target
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pituitary GnRH receptorsUnknown 2012
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression
Downstream effect
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare
Feedback intact?
—
No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression
Origin
—
Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability
Antibody development
—
—
02Dosage Protocols
Parameter
Survodutide
Triptorelin
Frequency
Once weekly
Every 1, 3, or 6 months per formulation
Evidence basis
Phase 2 RCT (obesity) · Phase 3 ongoing
Multiple Phase 3 RCTs · FDA-approved 1999
1-month depot
—
3.75 mg IM
Most common formulation for prostate cancer.
6-month depot
—
Administration route
—
Intramuscular (IM) — gluteal or deltoid
Indication: Prostate cancer
—
Advanced (metastatic or locally advanced)
Androgen deprivation therapy (ADT) backbone.
Indication: Endometriosis
—
3.75 mg monthly
FDA-approved; typically 6-month course.
Indication: Central precocious puberty
—
Pediatric use (≥2 years)Jia 2025
Weight-based dosing per FDA label.
Duration (prostate cancer)
—
Continuous or intermittent ADT protocolsPreston 2024
Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.
Monitoring
—
Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose
03Metabolic / Fat Loss Evidence
Parameter
Survodutide
Triptorelin
Primary fat target
Total body weight, visceral adipose tissue
—
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
—
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
—
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
—
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
—
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class
—
04Side Effects & Safety
Parameter
Survodutide
Triptorelin
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
—
Safety profile
Network meta-analysis: comparable safety to other GRAs
—
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
—
Injection site reactions
Expected with subcutaneous administration
Pain, erythema, sterile abscess (rare with depot formulations)
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
—
Initial flare symptoms
—
Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)
Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.
Cardiovascular events
—
MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025Preston 2024
Hot flashes
—
Very common (>60%); vasomotor instability
Bone loss / Osteoporosis
—
Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025
Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.
Metabolic syndrome
—
Weight gain, insulin resistance, dyslipidemia, diabetes risk
Gynecomastia / Breast tenderness
—
Common (10–20%); peripheral aromatization of residual androgens
Fatigue / Mood changes
—
Anemia, depression, cognitive changes reported in long-term ADT
Hepatotoxicity
—
Transient transaminase elevations; clinically apparent liver injury rare
Racial differences (ADT)
—
Black veterans show higher CV event rates vs White veterans on GnRH agonists
Absolute Contraindications
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Triptorelin
- ·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
- ·Pregnancy (Category X)
Relative Contraindications
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
Triptorelin
- ·Active cardiovascular disease — consider GnRH antagonist alternative
- ·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
- ·Severe urinary obstruction — may worsen during flare
- ·Osteoporosis or high fracture risk (requires bone-protective therapy)
05Administration Protocol
Parameter
Survodutide
Triptorelin
1. Reconstitution
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.
3. Timing
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.
6. Intermittent ADT protocol (optional)
—
Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.